Sign In
Buy IOBT
$0.0480
+0 (+0%)
At Close: Jul 08, 2026
IO Biotech Provides Update Following Pre-BLA Meeting with FDA
07:05am, Monday, 29'th Sep 2025
FDA recommends that IO Biotech not submit a Biologics License Application (BLA) based on the data from the IOB-013 clinical trial Company plans to design new registrational study for Cylembio for the
IO Biotech Announces Late-Breaking Abstract in Advanced Melanoma Selected for Oral Presentation at ESMO Congress 2025
08:05am, Tuesday, 23'rd Sep 2025
Oral presentation will highlight the results from the randomized Phase 3 trial (IOB-013/KN-D18) of IO102-IO103 cancer vaccine plus pembrolizumab for first-line (1L) advanced melanoma Poster presentati
IO Biotech, Inc. (IOBT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
11:41am, Tuesday, 09'th Sep 2025
IO Biotech, Inc. (NASDAQ:IOBT ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 7:45 AM EDT Company Participants Mai-Britt Zocca - Founder, President, CEO, Principal Financia
IO Biotech Announces Participation in Upcoming Investor Conferences
08:05am, Thursday, 04'th Sep 2025
NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, annou
IO Biotech, Inc. (IOBT) Upgraded to Buy: Here's What You Should Know
01:01pm, Wednesday, 03'rd Sep 2025
IO Biotech, Inc. (IOBT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
IO Biotech Reports Second Quarter 2025 Financial Results and Provides Business Highlights
04:05pm, Thursday, 14'th Aug 2025
Announced clinical improvement in progression free survival observed in pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (pembrolizumab) for the treatment of first-line advanced melanoma, but stati
IO Biotech: A Buying Opportunity Following Phase 3 Readout In Melanoma
04:17pm, Tuesday, 12'th Aug 2025
IO Biotech's phase 3 melanoma trial showed a strong PFS benefit, especially in true 1st-line and PD1-negative patients, despite narrowly missing statistical significance. I believe the FDA should acce
IO Biotech's cancer vaccine shows improvement in late-stage study goal
08:24am, Monday, 11'th Aug 2025
IO Biotech said on Monday its experimental cancer vaccine, in combination with Merck's Keytruda, showed improvement in a late-stage study goal, but was not statistically significant.
Patients treated with Cylembio (imsapepimut and etimupepimut, adjuvanted) plus pembrolizumab achieved improvement in progression free survival (PFS) compared to patients treated with pembrolizumab mon
NEW YORK, Aug. 10, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company, today announced the company will hold a conference call and webcast on Monday, August
IO Biotech, Inc. (IOBT) Just Flashed Golden Cross Signal: Do You Buy?
10:56am, Wednesday, 28'th May 2025
After reaching an important support level, IO Biotech, Inc. (IOBT) could be a good stock pick from a technical perspective. IOBT recently experienced a "golden cross" event, which saw its 50-day simpl
IO Biotech Announces Participation in Cowen 6th Annual Oncology Innovation Summit and Jefferies Global Healthcare Conference
08:05am, Tuesday, 20'th May 2025
NEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, announc
IO Biotech Reports First Quarter 2025 Financial Results and Business Highlights
08:05am, Wednesday, 14'th May 2025
Primary endpoint of pivotal Phase 3 trial (IOB-013/KN-D18) of lead investigational therapeutic cancer vaccine in patients with advanced melanoma still expected to readout in third quarter of 2025 Data
NEW YORK, April 26, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today
Preclinical data further support the potential of dual-antigen and TGF-β-directed vaccines to reshape the tumor microenvironment and drive anti-tumor immunity NEW YORK, April 25, 2025 (GLOBE NEWSWIRE
